Status: Not yet recruiting
TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy
This Phase 2a, randomized, double-blind, active-controlled study will evaluate the safety, tolerability, and preliminary efficacy of TriGlytza®-01 compared with metformin in adults with Type 2 diabetes inadequately controlled despite metformin therapy. Participants will be randomized to one of three treatment groups and treated for 16 weeks. Safety, glycaemic control, body weight, and other metabolic outcomes will be assessed
Participants needed: 48
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Myopharm LimitedUpdated: Jul 8, 2026Locations: 3
Eligibility criteria
Adults aged 18 to 70 years. [+6]
Type 1 diabetes mellitus or history of diabetic ketoacidosis. [+7]